Literature DB >> 20179718

Antiplatelet therapy: cangrelor for ACS-lessons from the CHAMPION trials.

David P Faxon.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20179718     DOI： 10.1038/nrcardio.2009.247

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN： 1759-5002            Impact factor:   32.419


× No keyword cloud information.
  7 in total

1.  Transitioning patients from cangrelor to clopidogrel: pharmacodynamic evidence of a competitive effect.

Authors:  Steven R Steinhubl; Jennifer J Oh; Julie H Oestreich; Suellen Ferraris; Richard Charnigo; Wendell S Akers
Journal:  Thromb Res       Date:  2007-07-13       Impact factor: 3.944

2.  Pharmacokinetics and pharmacodynamics of a bolus and infusion of cangrelor: a direct, parenteral P2Y12 receptor antagonist.

Authors:  Wendell S Akers; Jennifer J Oh; Julie H Oestreich; Suellen Ferraris; Mary Wethington; Steven R Steinhubl
Journal:  J Clin Pharmacol       Date:  2009-09-24       Impact factor: 3.126

3.  Prasugrel versus clopidogrel in patients with acute coronary syndromes.

Authors:  Stephen D Wiviott; Eugene Braunwald; Carolyn H McCabe; Gilles Montalescot; Witold Ruzyllo; Shmuel Gottlieb; Franz-Joseph Neumann; Diego Ardissino; Stefano De Servi; Sabina A Murphy; Jeffrey Riesmeyer; Govinda Weerakkody; C Michael Gibson; Elliott M Antman
Journal:  N Engl J Med       Date:  2007-11-04       Impact factor: 91.245

4.  Prognostic significance of periprocedural versus spontaneously occurring myocardial infarction after percutaneous coronary intervention in patients with acute coronary syndromes: an analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial.

Authors:  Abhiram Prasad; Bernard J Gersh; Michel E Bertrand; A Michael Lincoff; Jeffrey W Moses; E Magnus Ohman; Harvey D White; Stuart J Pocock; Brent T McLaurin; David A Cox; Alexandra J Lansky; Roxana Mehran; Gregg W Stone
Journal:  J Am Coll Cardiol       Date:  2009-07-28       Impact factor: 24.094

5.  Ticagrelor versus clopidogrel in patients with acute coronary syndromes.

Authors:  Lars Wallentin; Richard C Becker; Andrzej Budaj; Christopher P Cannon; Håkan Emanuelsson; Claes Held; Jay Horrow; Steen Husted; Stefan James; Hugo Katus; Kenneth W Mahaffey; Benjamin M Scirica; Allan Skene; Philippe Gabriel Steg; Robert F Storey; Robert A Harrington; Anneli Freij; Mona Thorsén
Journal:  N Engl J Med       Date:  2009-08-30       Impact factor: 91.245

6.  Intravenous platelet blockade with cangrelor during PCI.

Authors:  Deepak L Bhatt; A Michael Lincoff; C Michael Gibson; Gregg W Stone; Steven McNulty; Gilles Montalescot; Neal S Kleiman; Shaun G Goodman; Harvey D White; Kenneth W Mahaffey; Charles V Pollack; Steven V Manoukian; Petr Widimsky; Derek P Chew; Fernando Cura; Ivan Manukov; Frantisek Tousek; M Zubair Jafar; Jaspal Arneja; Simona Skerjanec; Robert A Harrington
Journal:  N Engl J Med       Date:  2009-12-10       Impact factor: 91.245

7.  Platelet inhibition with cangrelor in patients undergoing PCI.

Authors:  Robert A Harrington; Gregg W Stone; Steven McNulty; Harvey D White; A Michael Lincoff; C Michael Gibson; Charles V Pollack; Gilles Montalescot; Kenneth W Mahaffey; Neal S Kleiman; Shaun G Goodman; Maged Amine; Dominick J Angiolillo; Richard C Becker; Derek P Chew; William J French; Franz Leisch; Keyur H Parikh; Simona Skerjanec; Deepak L Bhatt
Journal:  N Engl J Med       Date:  2009-12-10       Impact factor: 91.245
  7 in total
  2 in total

Review 1.  G-protein-coupled receptors signaling pathways in new antiplatelet drug development.

Authors:  Paul A Gurbel; Athan Kuliopulos; Udaya S Tantry
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-01-29       Impact factor: 8.311

2.  The P2Y(12) antagonists, 2MeSAMP and cangrelor, inhibit platelet activation through P2Y(12)/G(i)-dependent mechanism.

Authors:  Binggang Xiang; Guoying Zhang; Hongmei Ren; Manjula Sunkara; Andrew J Morris; T Kent Gartner; Susan S Smyth; Zhenyu Li
Journal:  PLoS One       Date:  2012-12-06       Impact factor: 3.240
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.